CEO’s Bold Stock Sale Shakes Up Merit Medical Systems

New insider activity at Merit Medical Systems ( (MMSI) ) has taken place on May 29, 2025.

President & CEO Fred Lampropoulos has made a significant move by selling 20,000 shares of Merit Medical Systems stock, amounting to a total value of $1,930,800.

Recent Updates on MMSI stock

In the last 24 hours, Merit Medical Systems has seen significant developments, primarily driven by its acquisition of Biolife Delaware for $120 million. This strategic move is expected to enhance Merit’s product portfolio and contribute to revenue growth, although it may be slightly dilutive to 2025 financial performance due to transaction-related expenses. Analysts have responded positively to this acquisition, with Piper Sandler, Canaccord, and Wells Fargo raising their price targets for the company. Piper Sandler updated its model to reflect the Biolife transaction and segment revenue recasting, while Canaccord noted the acquisition and reaffirmation of FY25 guidance. Wells Fargo highlighted the acquisition’s expected revenue addition and its impact on earnings per share. These developments suggest a positive outlook for Merit Medical, despite potential macroeconomic challenges.

Spark’s Take on MMSI Stock

According to Spark, TipRanks’ AI Analyst, MMSI is a Outperform.

Merit Medical Systems’ overall stock score is driven by strong financial performance and strategic corporate events that support growth. The earnings call provided a positive outlook, albeit with some challenges from tariffs and EPS guidance reduction. The valuation appears stretched, and technical indicators suggest a cautious near-term view.

To see Spark’s full report on MMSI stock, click here.

More about Merit Medical Systems

YTD Price Performance: -1.71%

Average Trading Volume: 754,483

Technical Sentiment Signal: Buy

Current Market Cap: $5.7B